Skip to content

BmemHLA : Origins of the Heterogeneity of the Anti-HLA Memory B Cells in Kidney Transplantation

BmemHLA : Origins of the Heterogeneity of the Anti-HLA Memory B Cells in Kidney Transplantation

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06956469
Acronym
BmemHLA
Enrollment
75
Registered
2025-05-04
Start date
2025-06-15
Completion date
2028-12-15
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunology, Kidney Transplantation

Keywords

Kidney, Memory B Cell, Anti-HLA antibodies, Allogeneic events, Transplantation

Brief summary

This study will describe the transcriptomic and phenotypic characteristics of anti-HLA memory B cells by comparing five groups of patients awaiting renal transplantation: patients with a single history of pregnancy, transfusion or failure of a first renal transplant requiring transplantectomy within 3 months of transplantation, or after 3 months, and patients without an immunizing allogeneic event. The hypothesis is that these five contexts induce different types of memory B cells with different modalities of reactivation and post-transplant pathogenicity.

Detailed description

In kidney transplantation, the production of anti-HLA antibodies directed against the donor (DSA for Donor Specific Antibodies) can be responsible for humoral rejection, the main cause of long-term graft loss. Reactivation of anti-HLA memory B cells after transplantation is thought to play a major role in DSA production and the occurrence of humoral rejection. The investigators hypothesize that the nature and the function of anti-HLA memory B cells could differ depending on how they were initially generated. Several sensitizing events can lead to the production of anti-HLA memory B cells, but differ in terms of their inflammatory environment and the duration of allo-antigen exposure: pregnancy, transfusion or a previous transplantation. For the last group, the investigators want to distinguish two situations: kidney-transplanted patients that had an early transplantectomy due to thrombosis or that had an antibody-mediated rejection. Finally, patients can have anti-HLA antibodies without any sensitizing event identified. The investigators will first use an unbiased approach to test if anti-HLA memory B cells are heterogeneous. The investigators will perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. The investigators will further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.

Interventions

OTHERIdentification of types of anti-HLA-specific memory LBs

Using blood sample, it will be perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. It will be further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult kidney transplantation candidate at CHU de Bordeaux * Sensitized against class I HLA * Only on type of sensitizing event among : transfusion, pregnancy, previous transplantation, no senitizing event

Exclusion criteria

* Pediatric kidney transplantation candidate at CHU de Bordeaux * Rituximab injection * Ongoing treatment with immunosuppressive drugs * Non-cutaneous carcinoma, chronic viral infection * Acute infection * Recent vaccination (\<1 month)

Design outcomes

Primary

MeasureTime frameDescription
Memory B cell heterogeneityAt inclusionMemory B cell heterogeneity by single cell RNA sequencing

Secondary

MeasureTime frameDescription
CytometryAt inclusion (Day 0), second visit (up to18 months) , third visit (up to 24 months)Memory B cell heterogeneity by flow cytometry

Contacts

Primary ContactClaire LEIBLER, MD
claire.leibler@chu-bordeaux.fr05 57 82 21 46
Backup ContactJonathan VISENTIN, PharmD, PhD
jonathan.visentin@chu-bordeaux.fr05 57 82 24

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026